New York Times Examines How Research Into HIV-Positive Long-Term Nonprogressors Could Lead to AIDS Vaccine
May 3, 2005
The New York Times on Tuesday examined how the study of long-term nonprogressors -- HIV-positive people who do not take antiretroviral drugs but whose disease is not progressing to AIDS -- potentially could help in the development of an AIDS vaccine. According to Dr. Jay Levy, director of the University of California-San Francisco's Laboratory for Tumor and AIDS Virus Research, approximately 5% of HIV-positive people can remain "medicine-free and still healthy" 10 years after becoming infected, the Times reports. However, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, defines nonprogressors as HIV-positive people not on a treatment regimen who have "so little virus in their blood that it cannot be routinely detected," and he said that only about 0.2% to 0.4% of HIV-positive people fall into this category, according to the Times. Finding long-term nonprogressors to participate in clinical research "is challenging," the Times reports. "The disappointing thing is that there's no consensus about what the long-term nonprogressors do. Different things explain it in different people," Martin Delaney, founder of the HIV information and advocacy organization Project Inform, said.
Alabama Department of Corrections Asks Federal Judge to Dismiss Contempt Motion Filed by HIV-Positive Inmates
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.